Appclon announced on the 5th that it has completed the registration of a US divisional patent for the CAR-T therapy 'AT101,' which is currently in Phase 2 clinical trials.
The previously registered US patent for AT101 in 2022 covered CAR-T therapy using the h1218 antibody. The newly acquired US divisional patent additionally encompasses the components of AT101, including the antibody.
The company explained that this patent registration secures broader rights for CAR-T therapies.
CAR-T therapies targeting CD19 for hematologic cancers, such as Kymriah, Yescarta, Tecartus, and Breyanzi, all use the mouse-derived 'FMC63' antibody. Due to domestic and international patent barriers related to the same antibody, commercialization of CAR-T therapies using it is practically difficult.
AT101 uses the independently developed 'h1218' humanized antibody. It binds to a new epitope and features superior efficacy and longer-lasting therapeutic effects compared to existing therapies. The Phase 2 clinical trial is progressing smoothly, with interim results expected to be announced in the second half of this year, followed by plans to pursue expedited approval.
An Appclon representative stated, "By acquiring the US divisional patent for AT101, the expansion of the scope of rights has enhanced our business competitiveness," adding, "We will continue to strengthen global rights acquisition going forward."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
